© 2026 Alchemist Worldwide Ltd,
All Right Reserved
Analgin, also known as metamizole, arrived on the pharmaceutical scene in the early 20th century. German chemists were searching for dependable painkillers that didn’t lean so heavily into the side effects of morphine or aspirin. It didn’t take long before Analgin became a go-to for fever and pain relief—a reputation that stuck, particularly across Eastern Europe, Asia, and South America. Some countries later pushed back because of safety concerns, especially serious cases of agranulocytosis. Still, demand hasn’t faltered in many places where people rely on over-the-counter, wallet-friendly options for fast relief.
Most folks spot Analgin in pill form, though injectable versions find their way into both clinics and ambulances. The substance itself acts fast and targets moderate to severe pain, with a big role in taming fever when regular acetaminophen or ibuprofen just won’t cut it. The drug works as a non-opioid analgesic and antipyretic, meaning it doesn’t carry the baggage of addiction or constipation that opioids often do. Health workers tend to reach for Analgin during emergencies or surgeries when swelling or pain needs a quick fix. Shelf life hangs around three to five years under normal storage; potency doesn’t slip much stuck on a pharmacy shelf if humidity and light stay out.
Analgin’s powder shimmers white or slightly yellow, almost odorless, letting off a bitter taste. Its chemical label reads sodium 2,3-dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-methanesulfonate, with a molecular formula of C13H16N3NaO4S. It dissolves well in water but not so much in alcohol or ether. High temperatures break it down before reaching its melting point, which falls near 125°C. Pharmacies and distributors lean on this reliable stability, especially in hot climates. On the molecular level, its sulfonate group boosts solubility, which speeds the delivery through the blood and kicks in the pain-reducing effects in less than an hour for most people.
Analgin comes packed in different strengths, usually 500 mg per tablet for adults. Injectable solutions stay standardized at 500 mg or 1000 mg per vial, ready to take on post-surgery, trauma, or severe infection cases. Labels must list the batch number, manufacturing and expiry dates, dosage directions, and a big, bold warning about rare but severe blood reactions. Most labels mention national or World Health Organization monographs to prove the batch matches global standards for purity and quality. U.S. and Australian regulators pulled prescriptions for Analgin, though, so labeling there only covers research or special cases.
The process behind Analgin manufacturing calls for chemists who know their way around sulfonic acids and pyrazolone rings. It usually starts by methylating phenylhydrazine to build the pyrazolone backbone, then sulfonating that structure with methanesulfonic acid. Sodium hydroxide neutralizes the acid, letting sodium salt form and crystallize. Industrial plants depend on large-scale reactors, lots of cooling, and strong controls over waste because the byproducts can linger in water unless filtered. Some manufacturers recycle solvents, taking a page from modern green chemistry approaches that cut down on chemical waste and energy costs.
Analgin shifts easily during chemical tests—oxidizing agents split the pyrazolone ring, and strong acids reattach the methyl group, steering research into more stable compounds. Derivatives, including isopropyl and butyl forms, turn up in research that aims to dodge toxic side effects. Chemists keep tweaking substitutions on the aromatic ring, betting on better efficacy with lower risk. Analgin holds up against light, but mixing with certain antibiotics can slice its half-life in half. Every change brings a mix of gains and drawbacks, but every step builds our understanding of keeping pain relief safe and effective.
Analgin wears many badges worldwide. Pharmacists might call it metamizole, dipyrone, dypyrone, or noramidopyrine methanesulfonate. In Russia, baralgin or spazmalgon refer to Analgin blends with spasmolytics. Latin America sees Novalgin and Neonalgin, tucked into equal doses as stand-alone tablets or combos with antispasmodics. No matter the region or brand, Analgin sits among the most recognized names in pain relief, especially where alternatives cost more or cause other problems.
Hospitals keep an eye out for adverse reactions—analysts check batches for heavy metals, microbial contamination, and color impurities under strict rules. World Health Organization guidelines set a low bar for impurity levels, and most countries demand regular audits of plants. Staff regularly remind patients about agranulocytosis, a potentially deadly drop in white blood cells that remains rare but serious enough to prompt blood tests after repeated or high doses. Where the law allows over-the-counter sales, front-line pharmacists press patients for their health backgrounds, steering at-risk groups to safer alternatives. Labs depend on well-calibrated equipment, transparent record-keeping, and rapid recall systems, aiming to spot poor-quality pills or counterfeits before they ever reach shelves.
Doctors and nurses reach for Analgin mostly for strong pain, high fever, and painful conditions not easily dulled by regular painkillers. Ambulance teams use injections to cut pain fast—think car accidents, broken bones, kidney stones, or acute appendicitis. In veterinary care, Analgin soothes pain in large animals, like horses or cattle, especially when surgery isn’t an option. Low cost keeps Analgin in public health toolkits, especially after natural disasters or war, where stockpiling expensive drugs can’t keep pace with local demand. Community clinics in many developing nations pour most of their pain management budgets into Analgin, using decades of experience to strike a balance between relief and safety.
Research teams circle back to Analgin year after year, hoping to crack the puzzle of serious side effects. Some labs focus on understanding precisely how the drug disrupts pain pathways at the cellular level. Ongoing studies run head-to-head tests of Analgin against newer non-steroidal options, measuring pain scores, blood risks, and cost side by side. Scientists in India and Eastern Europe push for better assays to detect blood disorders early and flag high-risk patients before trouble starts. Drug developers look for tweaks to the compound that trim toxicity while keeping the affordable, effective pain control. The most exciting research uses genetic testing to predict which patients face higher risks, offering hope for the safest possible prescribing.
Cases of agranulocytosis continue to command headlines—sometimes rare, sometimes clustered in specific genetics or populations. Over the years, data has painted a mixed picture: big studies from Latin America and Russia put incidents well below one in ten thousand, but isolated hotspots in Europe prompted tougher bans after clusters in the 1970s and 80s. Animal experiments mapped how dose, kidney function, and genetic mutations shift the risk. Toxicologists keep digging into how the drug’s metabolites interact with bone marrow, chasing early biomarkers of trouble. In nearly every high-dose or long-term case where problems struck, doctors pinned it on missed warnings, monitoring gaps, or mixing drugs without checking for interactions. People with autoimmune or blood disorders face far higher risks, reminding the industry to target careful recommendations and screening before dispensing.
Looking ahead, Analgin remains part of daily medical life in dozens of countries where stronger, newer drugs still cost too much or remain out of reach. Some research projects work on nanoparticle delivery or slow-release tablets to broaden avenues for safer use, especially for patients who can’t take common anti-inflammatories. Biotech firms in Asia and South America have started combining Analgin with plant-based painkillers in hopes of creating blended drugs that pull double duty. Digital health tools, powered by electronic prescribing records, help flag high-risk users at the point of sale. Training programs and outreach campaigns hope to keep the public aware of the hidden risks, pushing an ongoing balancing act—giving relief to the many, while keeping rare tragedies at bay. As pain management keeps evolving, Analgin’s story reminds us that medicine never stops learning, blending old remedies with new science and hard-won experience.
Life sometimes throws us pain that can turn a good day upside down. Analgin, also known as metamizole, grabs attention in pharmacies mainly because of its power to chase away stubborn headaches, toothaches, and muscle pain. For years, people have counted on this drug for fast relief when the usual aspirin or acetaminophen doesn’t do the trick. Growing up, I remember seeing that green-and-white box in my grandmother’s medicine cabinet—she always reached for it after long days in the garden left her with aching knees.
Analgin belongs to the non-opioid analgesics. It targets pain signals by calming inflammation and blocking chemical messages in the body. Doctors in some countries hand it out for more intense pain—sometimes after surgery, sometimes for high fever that laughs off weaker drugs. The World Health Organization recognizes its usefulness. In many places, it fills a much-needed gap for people who need strong pain relief but want to avoid narcotics. Analgin’s price means people on a budget can get comfort without skipping a grocery trip.
Not everything about Analgin feels simple. Many countries (the US included) keep it off shelves because of rare but serious side effects. The big concern: agranulocytosis. This reaction can drop white blood cell counts and make the body lose its main defenders against infection. The risk remains low—estimated between 1 in 10,000 to 1 in 1,000,000—but the outcome can be severe. I know someone from Europe who caught a regular flu that exploded into bedsheet-soaking fever after an unlucky spell with this drug. He recovered, but it was no quick fix.
Some countries trust their monitoring systems enough to keep Analgin on the market. In Germany, Brazil, and Russia, you’ll find it in painkillers even for kids, although always with clear warnings and strict prescription rules. Doctors there track side effects closely. Education plays a big role, making sure people know to tell their physician about allergies or other immune problems before popping a pill. When tight regulations and good public health surveillance join forces, the risk for the average person falls even lower.
If you’re thinking of reaching for Analgin, it’s smart to weigh pros and cons, just like any strong medicine. Quick fixes can hide deeper problems; recurring pain signals that something isn’t right and treating symptoms alone rarely helps in the long run. Pain with fever, swelling, or weight loss deserves a checkup. People with a history of blood disorders or compromised immunity often do best skipping Analgin altogether.
For millions, Analgin brings affordable and reliable pain relief. Medical professionals and policymakers face tough decisions, choosing between access and safety. My own experience and the stories of family and friends shape my belief: good medicine isn’t just about what works fast, but what people can use safely over time. Clear conversations between doctor and patient, balanced with strong research and common sense, give Analgin a lasting role where it’s used responsibly.
Analgin, also called metamizole, helps many folks fight pain and fever. In some places outside the United States, you’ll find Analgin still on pharmacy shelves, and for good reason: it works fast. Growing up, I saw neighbors reach for this drug during migraines, dental pain, and high temperature. With just a tablet, people felt real relief when other medications barely touched their pain.
Even though Analgin can take away pain, serious side effects get swept under the rug in casual conversations. The biggest worry centers on agranulocytosis. This condition, where your white cells drop to a dangerously low level, can leave someone wide open to infections—sometimes with fatal consequences. In Europe, reports from drug safety agencies point out that even with rare occurrence, the outcome can devastate families. Hospital medical teams often look for unexplained fevers or sore throats in people who’ve used Analgin, because these might signal a drop in those crucial blood cells.
I’ve watched a family friend break out in hives and struggle to breathe after a dose. Allergic reactions range from simple skin rashes to anaphylactic shock. Some experience swelling in the face, low blood pressure, and difficulty breathing. In a busy emergency room, these symptoms pop up fast and must be treated immediately. Reports in the European Journal of Clinical Pharmacology show that allergic reactions from Analgin can happen to people who have never had drug allergies before.
After taking Analgin, patients sometimes complain of nausea, vomiting, or stomach pain. These unpleasant side effects usually go away once the drug leaves your system, but they still cause discomfort and worry. Longer use, especially in high doses, raises the risk of kidney problems. For people with weaker kidneys, Analgin use may push their organs into deeper trouble, and tracking kidney function becomes vital. Studies from hospitals in South America document these concerns regularly.
Analgin can drop blood pressure, especially if injected quickly or in large doses. This drop gets more pronounced in older adults or people with existing circulation issues. Women who are pregnant or breastfeeding should steer clear. Research is still new here, but the dangers of fetal harm and early labor push many doctors to recommend safer drugs.
With all these side effects on the table, Analgin isn’t always the best painkiller. Countries like the U.S. and U.K. pulled it from the market. In places where it’s still sold, doctors urge blood tests if patients need a longer course of treatment. Better education and honest conversations about risks help families make safer choices. Good alternatives like acetaminophen and ibuprofen provide relief, though each drug comes with its own risks—just different ones from Analgin.
Learning about Analgin’s side effects changes the way we handle pain. Armed with this knowledge, people weigh comfort against possible dangers more carefully.
Parents always want to ease their child’s pain and fever. The medicine cabinet at home often has a few trusted options, and some folks might remember Analgin (also called metamizole) from their own childhood. This painkiller holds a tricky spot in medical history. In some countries, you’ll still find it on pharmacy shelves. In others, like the US and much of Europe, it’s either banned or heavily restricted. The question always lingers: does it pose a risk to growing bodies?
Analgin’s quick action and reputation for cutting through high fevers and sharp aches fueled its popularity for decades. For a long time, doctors handed it out for everything from toothaches to post-surgery pain. The catch: Analgin sometimes sparks a rare but dangerous reaction called agranulocytosis. That’s when the white blood cell count drops, making it easier for infections to take hold. Kids, with their developing immune systems, don’t handle that risk very well.
Research and health records point to the connection between Analgin and agranulocytosis. In the late twentieth century, several studies tracked cases popping up around patients who took this drug. Europe started to rethink its use and many countries pulled it from the market. Places like Germany kept it around, but doctors grew more cautious. Even in Russia, Brazil, and India—where Analgin sits in medicine cabinets—medical professionals don’t look at it as their first line for children.
According to the World Health Organization and European Medicines Agency, the incidence of life-threatening side effects remains low — hovering around one or two cases per million users every year — but those numbers don’t comfort parents faced with more familiar, less risky options like acetaminophen or ibuprofen. Both alternatives, when given as instructed, rarely have such severe side effects and have been under far stricter surveillance.
As a parent, I search for what works and what won’t send me running back to the clinic with more problems. Talking with healthcare workers, I found they almost always reach for acetaminophen or ibuprofen when treating kids with fever or pain. The reason is straightforward: years of use, a known track record, and nearly every guideline supports them. In conversations with pediatricians, the mood shifts whenever Analgin comes up. There’s always a frown or a gentle warning about its risks.
That isn’t to say every dose of Analgin leads to disaster. Millions use it without incident. In places with limited medicine choices, doctors might use Analgin out of necessity, especially for stubborn, high fevers. In those scenarios, many practitioners watch kids closely for reactions and steer clear of long-term or repeat use.
Clear labels, better training, and national rules help push parents and doctors towards the safest choices. Pharmaceutical companies and health ministries play a big part here. If a drug has a serious but rare risk, warnings need to be loud and easy to understand. Families deserve real advice—not just a prescription.
I believe trust in medicine grows when parents know why doctors make the picks they do. Where safer options can do the job, there’s little reason to roll the dice with Analgin, especially for young kids. More countries have moved in that direction, and it’s hard to argue with a decision shaped by decades of evidence and concern for children’s health.
A lot of people reach for Analgin to chase away headaches or stubborn tooth pain. Its reputation as a reliable painkiller often comes before any talk of side effects or drug interactions. Some folks remember seeing parents or grandparents trust Analgin, even though medical advice keeps changing. One thing people rarely talk about: the risk of mixing Analgin with other medications. It might seem harmless, but real-world stories can show how things can take a turn.
Combining different medications without checking interactions easily slips into daily routines. A neighbor’s tip about stacking painkillers or taking cold tablets at the same time might seem sensible. But, Analgin has a track record of some rare but very serious side effects. The risk of agranulocytosis, a dangerous drop in white blood cells, hangs over Analgin. Pairing Analgin with certain antibiotics or anti-inflammatory medications can raise that risk even higher. Science backs this: a 2016 study in Eastern Europe saw complications in patients who used Analgin together with sulfa drugs and antidepressants.
Mixing Analgin and blood thinners like warfarin can increase bleeding, as Analgin thins the blood a bit on its own. People managing heart disease often take several medications, so unexpected side effects become more likely. It isn’t just about chemical clashes; the kidneys get hit hard when painkillers play together. Patients with kidney issues can see their condition grow worse if Analgin and ACE inhibitors end up in their daily routine.
Some general practitioners, under pressure of full clinics, scribble prescriptions or tell patients, “This should be fine together,” without digging deep into all the medications involved. Hospital records from Central Asia flagged cases where unexplained rashes or fevers in patients were due to overlooked Analgin combinations. As someone with healthcare work experience, I’ve seen pharmacists spot weird combos that nearly got missed. It takes just one alert pharmacist to prevent serious harm.
People can keep themselves safe by keeping a real, up-to-date medication list. Not just prescription pills—herbal teas, supplements, or over-the-counter cold remedies all count. A printed list in a wallet or a note on your phone could make all the difference in an emergency room. Pharmacists hold a goldmine of practical knowledge about drug interactions. Regular chats with them before picking up a new medicine go a long way in avoiding trouble.
Reliable sources like the World Health Organization and national drug agencies post warnings and updates about Analgin and its mixing risks. Checking those websites doesn’t take as long as people imagine. And telling your doctor about all your medications—no matter how minor they might seem—builds a real partnership for safe care. This approach puts the focus on the person, not just the pill.
Getting doctors and pharmacists to talk directly more often could catch problems early. Electronic record systems help spot dangerous combos, but pen and paper can't always keep up. Regulators have started stricter controls in some countries, but access remains easy in others. For people who need pain relief but want to avoid surprises, safer alternatives and close supervision can dodge the traps that Analgin might set when combined with the wrong partners.
Putting all these precautions into practice doesn’t complicate life. Instead, it means smarter, safer choices every day—and not learning the hard way about what Analgin can do when mixed with the wrong medications.
Analgin, also called metamizole, has a long history as a pain and fever-relieving medicine. I grew up hearing about Analgin from relatives in Eastern Europe, where it was as common in home medicine cabinets as aspirin is in the United States. Even though it's widely used in some countries, Analgin rarely appears in American pharmacies because of concerns about side effects and stricter approval standards. When someone talks about dosage, it’s really about safety—especially with medicines that aren't universally accepted.
Facts matter here. For adults and teenagers over 15, most doctors suggest a single oral dose of 500 to 1000 milligrams. A physician might give another dose four to six hours later if the earlier one didn’t help enough, but the daily maximum shouldn’t go past 4000 milligrams. For children, things get more specific. The dose often depends on body weight, usually between 10 to 20 milligrams per kilogram, spaced about every six hours. That's not something anyone should guess—using a kitchen scale doesn’t cut it. Only calibrated dosing tools and a trained doctor’s advice work for kids, especially since children’s livers and kidneys can’t deal with drugs as efficiently as adult organs.
I remember once reading about someone who doubled their painkiller dose thinking it would “work faster,” and it ended with a trip to the emergency room. Analgin can lower fever and pain fast, but a larger dose raises the chance of rare side effects, like agranulocytosis—a severe drop in certain white blood cells. This isn’t just a scary-sounding word; it’s life-threatening because it tanks the body’s ability to fight infection. European studies show it happens in about one in a million treatments, but the severity has made some countries remove Analgin from their shelves.
People with existing blood conditions, liver or kidney problems, or reactions to nonsteroidal anti-inflammatories might face much higher risks. I sat across from a pharmacist once who told me that a customer insisted on Analgin for their elderly parent, not knowing the parent's strong heart medication could interact dangerously. That's an example of why self-medication goes wrong, especially when crossing borders or using online pharmacies.
Sticking to the recommended doses matters not just because that's what it says on the box. Medical supervision actually saves lives. Analgin can help people who can't tolerate other painkillers, but a doctor’s checkup should come first—running checks for allergies, drug interactions, and underlying risks. Pharmacies in countries that still sell Analgin often require a prescription. That step protects people who might grab it in a hurry without understanding their own risk factors. In places with looser access, many people still rely on family traditions rather than verified information.
Health information is everywhere online, but anyone using Analgin should look for reputable health provider guidance—ideally from government health departments or licensed pharmacists. I suggest people double-check dose instructions and keep an eye on new symptoms like unexplained fever, sore throat, or mouth ulcers. Those could signal early blood problems, which need immediate help. Sticking to safe doses does not only stay within the guidance—it also protects the people we care about from hidden risks.
| Names | |
| Preferred IUPAC name | sodium 2-[(2,3-dimethylphenyl)amino]-1,3-dimethyl-1H-pyrazole-5-methanesulfonate |
| Other names |
Metamizole Dipyrone Novalgin Analginum Dipiron |
| Pronunciation | /ˈæn.əl.dʒɪn/ |
| Preferred IUPAC name | sodium 2-[(2,3-dimethylphenyl)amino]-1,3-dimethyl-1H-pyrazole-5-methanesulfonate |
| Other names |
Dipyrone Metamizole Novalgin Novaldine Noramidopyrine |
| Pronunciation | /ˈæn.æl.dʒɪn/ |
| Identifiers | |
| CAS Number | 50-78-2 |
| 3D model (JSmol) | `3D model (JSmol)` string for Analgin (Metamizole): ``` CCN(CC)S(=O)(=O)Nc1ccc(cc1)C(=O)N(N)C ``` |
| Beilstein Reference | 3491743 |
| ChEBI | CHEBI: dipyrone |
| ChEMBL | CHEMBL1438 |
| ChemSpider | 3240 |
| DrugBank | DB04817 |
| ECHA InfoCard | 100.003.044 |
| EC Number | 611-60-1 |
| Gmelin Reference | Gmelin 8213 |
| KEGG | D00945 |
| MeSH | D008564 |
| PubChem CID | 6158 |
| RTECS number | CQ2625000 |
| UNII | Q42T66VG0D |
| UN number | UN2811 |
| CAS Number | 68-89-3 |
| 3D model (JSmol) | `3D model (JSmol)` string for Analgin (Metamizole, also known as Dipyrone): ```string CC1=CC=C(C=C1)N(N=O)C(=O)N(C)C ``` This is the SMILES string for Analgin. |
| Beilstein Reference | Beilstein 4121899 |
| ChEBI | CHEBI:6587 |
| ChEMBL | CHEMBL1405 |
| ChemSpider | 2056 |
| DrugBank | DB01435 |
| ECHA InfoCard | echa.infocard:100.003.013 |
| EC Number | EC 3.1.1.37 |
| Gmelin Reference | 10303 |
| KEGG | D02121 |
| MeSH | D007486 |
| PubChem CID | 5120 |
| RTECS number | CN6556000 |
| UNII | G95688884E |
| UN number | UN1544 |
| Properties | |
| Chemical formula | C13H17N3O4S |
| Molar mass | 303.354 g/mol |
| Appearance | white crystalline powder |
| Odor | Odorless |
| Density | 1.19 g/cm³ |
| Solubility in water | sparingly soluble |
| log P | 0.2 |
| Acidity (pKa) | 5.57 |
| Basicity (pKb) | 3.96 |
| Magnetic susceptibility (χ) | -74.0e-6 cm³/mol |
| Refractive index (nD) | 1.502 |
| Viscosity | 1.70 mPa·s |
| Dipole moment | 4.44 D |
| Chemical formula | C13H17N3O4S |
| Molar mass | Sodium: 333.38 g/mol |
| Appearance | Analgin is typically a white or almost white, crystalline powder or tablets, odorless, with a slightly bitter taste. |
| Odor | Odorless |
| Density | 1.0 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 2.02 |
| Vapor pressure | Vapor pressure: Negligible |
| Acidity (pKa) | 3.77 |
| Basicity (pKb) | 3.75 |
| Refractive index (nD) | 1.541 |
| Dipole moment | 3.97 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 218.0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -45.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3381 kJ/mol |
| Std molar entropy (S⦵298) | 208.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -97.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3148 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | N02BB02 |
| ATC code | N02BB02 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes serious eye irritation, may cause allergic reactions, may damage blood. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | Keep out of reach of children. If swallowed, seek medical advice immediately and show this container or label. Avoid contact with eyes and skin. Use only as directed. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | >113°C |
| Autoignition temperature | Around 570°C |
| Lethal dose or concentration | LD₅₀ (rat, oral): 3,150 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Analgin: 3,150 mg/kg (oral, rat) |
| NIOSH | NS3500000 |
| PEL (Permissible) | 80 mg/m³ |
| IDLH (Immediate danger) | Not established |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | R52", "Pictogram GHS07 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | Keep out of reach of children. If medical advice is needed, have product container or label at hand. Read label before use. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | 186°C |
| Autoignition temperature | > 580°C |
| Lethal dose or concentration | LD50 (oral, rat): 3,120 mg/kg |
| LD50 (median dose) | 790 mg/kg (rat, oral) |
| NIOSH | NS3500000 |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | Analgin: 500 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Paracetamol Phenazone Aminophenazone Propyphenazone Phenylbutazone |
| Related compounds |
4-Aminoantipyrine Antipyrine Aminophenazone Phenazone |
